Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1996
Industry: Medical Devices (Minimally Invasive Procedures)
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in cardiology, gastroenterology, urology, radiology, and vascular surgery. The company's strategy focuses on product diversity, innovation, and strategic acquisitions to achieve market leadership. In 1996, the company completed several significant acquisitions, including EP Technologies, Symbiosis Corp., and assets of Endotech/MinTec, and announced an agreement to acquire Target Therapeutics in early 1997.
Key Financial Metrics
Revenue: Net sales for 1996 were $1.46 billion, a substantial increase from $1.8 million in 1979. International sales accounted for approximately 39% of net sales in 1996, up from 33% in 1995.
Profitability and Margins: The filing text does not provide specific values for net income, operating income, or gross margins for the fiscal year 1996. Management notes that managed care trends may result in price pressure and margin compression.
Cash Flow and Liquidity: Specific cash flow figures and liquidity ratios are not provided in the text. The company maintains a dedicated sales force of over 1,200 individuals and ships more than 95% of products within 24 hours, indicating low inventory backlog.
Debt: The text mentions a mortgage debt of approximately $300,000 on a property leased from a realty trust for the benefit of the CEO. A credit agreement dated June 7, 1996, is listed as an exhibit, but total debt figures are not stated in the provided text.
Valuation: As of March 14, 1997, the aggregate market value of common stock held by non-affiliates was approximately $7.1 billion. The closing stock price on that date was $64.75.
Material Changes and Acquisitions
The company's growth in 1996 was driven primarily by strategic acquisitions and alliances:
- Acquisitions in 1996:
- EP Technologies, Inc. (EPT): Acquired via stock-for-stock pooling (3.4 million shares) for electrophysiology catheters.
- Symbiosis Corp: Acquired for $153 million cash for endoscopy devices.
- Endotech/MinTec: Acquired for $72 million cash for stent grafts.
- Acquisitions in 1995: Included SCIMED (cardiology), CVIS (radiology), Vesica (urology), Meadox (vascular), and Heart Technology (cardiology).
- Strategic Alliance: Exclusive worldwide license with Medinol Ltd. to market stent products, including the NIR coronary stent.
- Proposed Acquisition: Agreement to acquire Target Therapeutics (neuro-endovascular) for 16.1 million shares, expected to close April 8, 1997.
Operational Changes: The company plans to consolidate domestic distribution activities into a new facility in Quincy, Massachusetts, and expects to close certain international manufacturing operations as part of a reorganization plan.
Outlook, Risks, and Contingencies
Management Commentary: Management believes the company has achieved "strategic mass" to better compete in a healthcare environment characterized by cost containment and consolidation. Integration of 1996 acquisitions is expected to be substantially complete by the end of 1997.
Risks and Contingencies:
- Regulatory and Reimbursement: An investigation by the Office of the Inspector General (OIG) regarding improper Medicare/Medicaid claims for cardiovascular devices is ongoing. The outcome is unpredictable and could materially affect the industry or the company.
- Legal Proceedings:
- C.R. Bard: Filed a patent infringement suit against SCIMED in February 1997.
- Johnson & Johnson: Multiple suits filed in Europe regarding the NIR stent and LEAP balloon, with cross-border infringement claims.
- Advanced Cardiovascular Systems (ACS): Arbitration concluded in March 1997; the company expects to dismiss actions regarding certain products but continue regarding the ELIPSE product.
- Integration Risk: The complexity of integrating numerous major transactions presents a significant degree of difficulty; failure could adversely affect operating results.
- Foreign Currency: International sales (39% of total) expose the company to foreign currency fluctuations, which may impact margins.
Investor Verification Checklist
- Verify the final financial impact of the 1996 acquisitions (Symbiosis, Endotech/MinTec, EPT) on consolidated earnings and cash flow.
- Monitor the status of the OIG investigation regarding Medicare/Medicaid reimbursement claims and potential sanctions.
- Track the resolution of patent litigation with C.R. Bard and Johnson & Johnson, specifically regarding the NIR stent and LEAP balloon.
- Confirm the closing of the Target Therapeutics acquisition and its integration timeline.
- Review the "Five-Year Selected Financial Data" and "Management's Discussion and Analysis" in the full 1996 Annual Report (Exhibit 13.1) for specific profit and cash flow figures not included in this summary.